|

Sonrotoclax Clinical Trials

14 actively recruiting trials across 7 locations

No change since August 2026

Also known as: B-cell Lymphoma-2 Inhibitor BGB-11417, BGB 11417, BGB-11417, BGB11417, Bcl-2 Inhibitor BGB-11417

Pipeline

Phase 1: 1Phase 2: 6Phase 3: 4Phase 1/2: 3

Top Sponsors

  • BeOne Medicines6
  • Ruijin Hospital1
  • Peking University People's Hospital1
  • Massachusetts General Hospital1
  • Fred Hutchinson Cancer Center1

Indications

  • Cancer14
  • Chronic Lymphocytic Leukemia6
  • Mantle Cell Lymphoma5
  • Refractory Mantle Cell Lymphoma2
  • Small Lymphocytic Lymphoma2

Other3 trials

Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis
Phase 2
Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy
Phase 2
Study of SA+X in the Treatment of Newly Diagnosed AML
Phase 2

Birmingham, Alabama3 trials

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

University of Alabama At Birmingham Hospital

Phase 1/2
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

University of Alabama At Birmingham Hospital

Phase 3
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

University of Alabama at Birmingham Cancer Center

Phase 3

Phoenix, Arizona2 trials

A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

Mayo Clinic Phoenix

Phase 1/2
BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma

Mayo Clinic Arizona

Phase 2

Duarte, California2 trials

A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

City of Hope National Medical Center

Phase 3
Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

City of Hope Medical Center

Phase 1

Laguna Hills, California1 trial

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

Uci Health Laguna Hills

Phase 3

Tampa, Florida1 trial

A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.

Moffitt Cancer Center

Phase 1/2

Boston, Massachusetts1 trial

Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLL

Massachusetts General Hospital

Phase 2

Seattle, Washington1 trial

Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma

Fred Hutch/University of Washington Cancer Consortium

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.